By Kate O’Rourke and Sarah Tilyou
San Francisco—Combination treatment with pembrolizumab and axitinib is emerging as a new standard of care for first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC), with benefit even in patients with poor-risk features, according to results of the KEYNOTE-426 trial.
OCTOBER 8, 2019